Buchumschlag

Real-world treatment patterns and survival in patients with ROS1-positive advanced non-small cell lung cancer in Canada and Europe

Real-world data on patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) remain scarce. In this descriptive observational retrospective cohort study, we describe characteristics, treatments, and real-world progression-free survival (rwPFS) and overall survival (OS) among patients w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Cheung, Winson (Verfasst von) , Lee, Adam (Verfasst von) , Bote de Cabo, Helena (Verfasst von) , Burdenski, Kathrin (Verfasst von) , Christopoulos, Petros (Verfasst von) , Pinto-Correia, Bárbara (Verfasst von) , Deshayes, Simon (Verfasst von) , Girard, Nicolas (Verfasst von) , Hindocha, Pooja (Verfasst von) , Madden, Áine (Verfasst von) , Mella, Marta (Verfasst von) , Moreira, Joana (Verfasst von) , Rizzi, Silvia (Verfasst von) , Abreu, Delvys Rodríguez (Verfasst von) , Soares, Marta (Verfasst von) , Thomas, Joseph (Verfasst von) , Han, Maria (Verfasst von) , Calvet, Christophe Y. (Verfasst von) , Emanuel, Gabrielle (Verfasst von) , Glassberg, Mrudula B. (Verfasst von) , Jacobs, Hazel (Verfasst von) , Rault, Caroline (Verfasst von) , Yuan, Yong (Verfasst von) , Chouaid, Christos (Verfasst von)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 6 March 2026
In: Current oncology
Year: 2026, Jahrgang: 33, Heft: 3, Pages: 1-18
ISSN:1718-7729
DOI:10.3390/curroncol33030152
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/curroncol33030152
Verlag, kostenfrei, Volltext: https://www.mdpi.com/1718-7729/33/3/152
Volltext
Verfasserangaben:Winson Y. Cheung, Adam Lee, Helena Bote de Cabo, Kathrin Burdenski, Petros Christopoulos, Bárbara Pinto-Correia, Simon Deshayes, Nicolas Girard, Pooja Hindocha, Áine Madden, Marta Mella, Joana Moreira, Silvia Rizzi, Delvys Rodríguez Abreu, Marta Soares, Joseph Thomas, Maria Han, Christophe Y. Calvet, Gabrielle Emanuel, Mrudula B. Glassberg, Hazel Jacobs, Caroline Rault, Yong Yuan and Christos Chouaid
Beschreibung
Zusammenfassung:Real-world data on patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) remain scarce. In this descriptive observational retrospective cohort study, we describe characteristics, treatments, and real-world progression-free survival (rwPFS) and overall survival (OS) among patients with ROS1-positive advanced NSCLC (de novo or recurrent) using secondary data pooled from clinical sites in Canada, France, Germany, Portugal, and Spain as part of the Oncology Evidence Network. Site-specific patient inclusion periods occurred between 2009 and 2023, with follow-up to 2024, allowing ≥1 year of potential follow-up at each site. In total, 108 patients were included, with most (n = 105; 97.2%) having a de novo diagnosis of advanced NSCLC. 103 patients (95.4%) received ≥1 line of systemic anticancer therapy (SACT), of which 65 (63.1%) received first-line targeted therapy, mostly crizotinib monotherapy (n = 45) or crizotinib-based regimens (n = 10), with a median (95% CI) rwPFS and OS of 14.0 (8.3-19.8) and 47.9 (27.3-not estimable) months, respectively. Thirty-eight of the 103 SACT-treated patients (36.9%) received first-line non-targeted therapy, mostly platinum-based chemotherapy (n = 26); median (95% CI) rwPFS and OS were 9.0 (7.5-11.0) and 29.3 (17.7-65.7) months, respectively. Results from this study indicated a tendency for longer survival using currently available ROS1-targeted versus non-targeted therapy for patients with ROS1-positive advanced NSCLC. Nevertheless, survival outcomes were limited, highlighting the importance of more effective emerging treatments for ROS1-positive disease.
Beschreibung:Veröffentlicht: 6. März 2026
Gesehen am 22.05.2026
Beschreibung:Online Resource
ISSN:1718-7729
DOI:10.3390/curroncol33030152

Ähnliche Einträge